ArticleCureus2025
Branch Retinal Vein Occlusion Revealing Previously Undiagnosed Systemic Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Branch retinal vein occlusion (BRVO) is a common cause of vision loss and frequently reflects an underlying systemic vascular disorder. Early systemic assessment is fundamental for preventing ocular and cardiovascular complications. This report describes the clinical case of a 61-year-old woman who presented with sudden, painless visual field loss in the left eye. Fundoscopic and angiographic findings confirmed superotemporal BRVO with macular edema. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy was initiated, and referral to a primary care physician for systemic evaluation was requested. However, due to the absence of a standardized referral protocol, the patient did not undergo prompt assessment. One week after the initial ophthalmologic visit, she presented to the emergency department with a severe headache and was found to have a hypertensive crisis. This case focuses attention on how retinal vascular occlusion (RVO) can be the first manifestation of an undetected systemic hypertension. It also marks the gaps in current systemic screening protocols for RVO and the need for closer collaboration between ophthalmologists and internal medicine specialists. A comprehensive and multidisciplinary evaluation of BRVO is indispensable for uncovering systemic risk factors and guiding treatment. Timely ocular therapy combined with systemic management can prevent irreversible visual loss and systemic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.